{"id":36537,"date":"2025-06-09T18:14:39","date_gmt":"2025-06-10T01:14:03","guid":{"rendered":"https:\/\/mygreenlab.org\/carbon-impact-reports\/"},"modified":"2025-12-02T05:52:21","modified_gmt":"2025-12-02T13:52:21","slug":"carbon-impact-reports","status":"publish","type":"page","link":"https:\/\/mygreenlab.org\/pt-br\/resources\/carbon-impact-reports\/","title":{"rendered":"Carbon Impact Reports"},"content":{"rendered":"\n\n \n\n \n Free Industry Analysis\n <\/sc-rich-text> \n

A data-rich analysis of 765 public and 290 private companies, cross-industry benchmarks, and the sector\u2019s alignment with global climate goals.<\/p>\n\n <\/sc-rich-text> \n Download Report\n <\/sc-button>\n <\/sc-cta-image>\n<\/sc-container>\n\n\n\n \n \n

Where the sector stands in 2025<\/h3>\n

This year\u2019s analysis shows a clear split in the industry\u2019s climate progress. Many biotech and pharma companies are doing real work to reduce the carbon footprint of their operations, and those efforts are aligning well with a 1.5\u00b0C pathway. But supply chain (Scope 3) emissions remain the biggest challenge keeping the sector\u2019s overall climate impact closer to 2\u00b0C. The data helps show where progress is happening, and where more support and action are still needed.<\/p>\n

Key Highlights:<\/h4>\n
    \n
  • Operational emissions are improving<\/strong>, aligning with a 1.5\u00b0C pathway. But once supply chains are included, the implied temperature rises to 1.9\u00b0C, keeping the sector closer to a near 2\u00b0C path overall.<\/li>\n
  • More companies are setting stronger climate targets.<\/strong>\u00a0Among those with the highest-quality disclosures, 52% now have medium-term Scope 1\u20132 targets aligned with a 1.5\u00b0C pathway, marking real progress on operational ambition.<\/li>\n
  • The largest companies continue to make steady reductions<\/strong>, cutting Scopes 1\u20132 emissions intensity by around 10% and Scope 3 by about 5%. Smaller and private companies, however, are generally moving in the opposite direction.<\/li>\n
  • Most emissions still come from supply chains<\/strong>\u2014about 75% for public companies and 88% for private companies\u2014highlighting why Scope 3 remains the defining challenge.<\/li>\n
  • More companies are joining the UN Race to Zero,\u00a0<\/strong>increasing from 38 to 42 companies this year, showing continued commitment despite a complex landscape.<\/li>\n<\/ul>\n\n <\/sc-rich-text> \n \n Download the full report\n <\/sc-button>\n <\/sc-rich-text>\n <\/sc-container>\n\n\n\n\n\n\n \n\n \n

     <\/p>\n

    Explore our comprehensive archive of industry carbon analysis and sustainability research spanning multiple years of data and insights.<\/p>\n\n <\/sc-rich-text>\n \n\n <\/sc-section-header>\n \n\n \n \n 2024\n <\/sc-rich-text>\n\n \n

    The biotech and pharma industry has the potential to become a global leader in addressing climate change and serve as a model for other industries.<\/p>\n\n <\/sc-rich-text>\n\n \n\n \n\n \n Download 2024 Report\n <\/sc-button>\n\n \n\n \n\n <\/sc-card> \n \n 2023\n <\/sc-rich-text>\n\n \n

    Analyzed 226 public and 147 private companies. Introduced collective supply chain initiatives: Energize, Activate, and Converge programs driving change.<\/p>\n\n <\/sc-rich-text>\n\n \n\n \n\n \n Download 2023 Report\n <\/sc-button>\n\n \n\n \n\n <\/sc-card> \n \n 2022\n <\/sc-rich-text>\n\n \n

    First comprehensive Scope 3 analysis across the value chain. Tracked industry progress since 2015 with 231 public and 151 private companies analyzed.<\/p>\n\n <\/sc-rich-text>\n\n \n\n \n\n \n Download 2022 Report\n <\/sc-button>\n\n \n\n \n\n <\/sc-card>\n <\/sc-grid>\n<\/sc-container>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2875,"featured_media":0,"parent":36244,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"","_seopress_titles_title":"Carbon Impact Report: Biotech & Pharma Industry Analysis","_seopress_titles_desc":"Download our comprehensive 2024 carbon emissions analysis of biotech and pharmaceutical companies. Discover industry trends and sustainability progress.","_seopress_robots_index":"","footnotes":""},"class_list":["post-36537","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/mygreenlab.org\/pt-br\/wp-json\/wp\/v2\/pages\/36537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mygreenlab.org\/pt-br\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/mygreenlab.org\/pt-br\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/mygreenlab.org\/pt-br\/wp-json\/wp\/v2\/users\/2875"}],"replies":[{"embeddable":true,"href":"https:\/\/mygreenlab.org\/pt-br\/wp-json\/wp\/v2\/comments?post=36537"}],"version-history":[{"count":16,"href":"https:\/\/mygreenlab.org\/pt-br\/wp-json\/wp\/v2\/pages\/36537\/revisions"}],"predecessor-version":[{"id":64938,"href":"https:\/\/mygreenlab.org\/pt-br\/wp-json\/wp\/v2\/pages\/36537\/revisions\/64938"}],"up":[{"embeddable":true,"href":"https:\/\/mygreenlab.org\/pt-br\/wp-json\/wp\/v2\/pages\/36244"}],"wp:attachment":[{"href":"https:\/\/mygreenlab.org\/pt-br\/wp-json\/wp\/v2\/media?parent=36537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}